デンドリット細胞におけるmRNA m6Aメチル化とYTHDF1によって制御される抗腫瘍免疫
Dali Han1,2,3, Jun Liu4,5,6, Chuanyuan Chen7,8,9
1Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. handl@big.ac.cn.
Nature
|February 8, 2019
まとめ
メッセンジャーRNA (mRNA) N6-メチアデノシン (m6A) メチレーションは,YTHDF1によって調節され,耐久的な抗腫瘍免疫を制御する. YTHDF1欠乏症はCD8+ T細胞の反応を高め,免疫療法の有効性を高める.
科学分野:
- 免疫学
- 分子生物学
- 癌 研究
背景:
- 腫瘍新抗原は,抗腫瘍免疫と免疫療法の反応に不可欠です.
- ネオアンチゲンの存在にもかかわらず,腫瘍の完全な除去は,しばしば不十分な免疫反応によって制限されます.
研究 の 目的:
- 抗腫瘍免疫の調節におけるmRNA N6-メチアデノシン (m6A) メチレーションとYTHDF1の役割を調査する.
- ネオアンチゲン表現とT細胞応答に対するYTHDF1の影響を調査する.
主な方法:
- Ythdf1欠乏症と野生型のマウスの比較分析
- CD8+ T細胞応答と腫瘍抗原のクロスプレゼンテーションの評価
- YTHDF1のメカニズムの調査は,m6Aマークのトランスクリプトとリソソームのカテプシンを含む.
主要な成果:
- Ythdf1欠乏したマウスは,抗原特異性CD8+T細胞の抗腫瘍反応を強めた.
- dendritic 細胞における YTHDF1 の喪失は,腫瘍抗原のクロスプレゼンテーションとT細胞のクロスプライミングを改善した.
- YTHDF1は,m6のAマークトランスクリプトに結合し,キャセプシン翻訳を増加させ,抗原のクロスプレゼンテーションを抑制する.
結論:
- YTHDF1は,m6Aメチル化によって永続的なネオアンチゲン固有の免疫を調節する.
- YTHDF1をターゲットにすることで,抗腫瘍CD8+T細胞応答とPD- L1免疫療法の有効性が向上します.
- YTHDF1は,がんの免疫療法を改善するための潜在的な治療目標です.
関連する概念動画
Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Epigenetic Regulation
33.0K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.0K
Epigenetic Regulation
3.6K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.6K
mTOR Signaling and Cancer Progression
4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.5K
MicroRNAs
3.5K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.5K
MicroRNAs
23.6K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.6K


